Characterization of the drugged human genome

Pharmacogenomics

Volumn 8, Issue 8, 2007, Pages 1063-1073

  Lauss, Martin ^a   Kriegner, Albert ^a   Vierlinger, Klemens ^a   Neohammer, Christa ^a  

^a ARC SEIBERSDORF RESEARCH GMBH   (Austria)

Author keywords

Chromosomal location; Drug targets; Druggable genome; Enrichment; Marketed drugs; Mendelian disorders; Tissue distribution

Indexed keywords

ABELSON KINASE; ABELSON KINASE 1; FLUDARABINE; IMATINIB; MEMBRANE RECEPTOR; PROMETHAZINE; RHODOPSIN LIKE 7 TRANSMEMBRANE RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHROMOSOMAL LOCALIZATION; DRUG MARKETING; DRUG TARGETING; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENETIC LINKAGE; HUMAN; HUMAN GENOME; LIGAND BINDING; MOLECULAR GENETICS; MOLECULAR INTERACTION; NONHUMAN; OFF LABEL DRUG USE; PHARMACOGENETICS; RECEPTOR OCCUPANCY; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

DATABASES, GENETIC; GENOME, HUMAN; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 34548751249     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.8.1063     Document Type: Article

References (26)

1. Golden JB: Prioritizing the human genome: knowledge management for drug discovery. Curr. Opin. Drug Discov. Devel. 6. 310-316 (2003).
2. Imming P. Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat. Rev Drug Discov. 5, 821-834 (2006).
3. Zheng CJ, Han LY, Yap CW et al.: Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol. Rev. 58, 259-279 (2006).
4. Overington JP. Al Lazikani B, Hopkins AL: How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996 (2006).
5. Hopkins AL, Groom CR: The druggable genome. Nat. Rev. Drug Discov. 1, 727-730 (2002).
6. Wishart DS, Knox C, Guo AC et al.: DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668-D672 (2006).
7. Zhang B, Kirov S, Snoddy J: WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 33, W741-W748 (2005).
8. Ashburner M, Ball CA, Blake JA et al.: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25-29 (2000).
9. Kanehisa M, Goto S, Hattori M et al.: From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 34, D354-D357 (2006).
10. Finn RD, Mistry J, Schuster-Bockler B et al.: Pfam: clans, web tools and services. Nucleic Acids Res. 34, D247-D251 (2006).
11. International Human Genome Sequencing Consortium: Finishing the euchromatic sequence of the human genome. Nature 431, 931-945 (2004).
12. Strausberg RL: The Cancer Genome Anatomy Project: new resources for reading the molecular signatures of cancer. J. Pathol. 195, 31-40 (2001).
13. Futreal PA, Coin L, Marshall M et al.: A census of human cancer genes. Nat. Rev Cancer 4, 177-183 (2004).
14. Whitfield ML, George LK, Grant GD, Perou CM: Common markers of proliferation. Nat. Rev. Cancer 6, 99-106 (2006).
15. Bejerano G. Pheasant M, Makunin I et al.: Ultraconserved elements in the human genome. Science 304, 1321-1325 (2004).
16. Redon R, Ishikawa S, Fitch KR et al.: Global variation in copy number in the human genome. Nature 444, 444-454 (2006).
17. Hamosh A, Scott AF, Amberger A Bocchini CA, McKusick VA: Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 33, D514-D517 (2005).
18. Wheeler DL, Barrett T, Benson DA et al.: Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 35, D5-D12 (2007).
19. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001).
20. Kim DH, Rossi JJ: Strategies for silencing human disease using RNA Interference. Nat. Rev. Genet, 8, 173-184 (2007).
21. Reichert JM, Vaige-Archer VE: Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 6, 349-356 (2007).
22. Rhodes DR, Yu J, Shanker K et al.: Large-scale meta-analysis of cancer rnicroarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl Acad. Sci. USA 101, 9309-9314 (2004).
23. Glinsky GV, Berezovska O, Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients wtth multiple types of cancer. J. Clin. Invest. 115, 1503-1521 (2005).
24. van't Veer LJ, Dai H, van de Vijver MJ et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
25. Pomeroy SL, Tamayo, P, Gaasenbeek M et al.: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442 (2002).
26. Beer DG, Kardia SL, Huang CC et al.: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8, 816-824 (2002).